Does Cosentyx Reduce COVID-19 Vaccine Protection?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other autoimmune conditions, suppresses parts of the immune response that could blunt vaccine-induced immunity. Studies show it reduces antibody responses to COVID-19 vaccines, particularly mRNA types like Pfizer and Moderna, with lower neutralizing antibody titers compared to healthy controls or patients on other biologics.[1][2] Real-world data from psoriasis patients indicate 20-30% weaker seroconversion rates, though T-cell responses often remain intact, providing some cellular protection.[3]
How Does Cosentyx Specifically Impact Vaccine Response?
It targets IL-17A, disrupting Th17 cell activity involved in mucosal immunity and inflammation. This leads to:
- Diminished IgG and neutralizing antibodies post-vaccination (e.g., 50-70% lower peak levels in some cohorts).[1]
- Slower waning of antibodies, but overall reduced peak protection against variants like Delta or Omicron.[4]
No evidence suggests complete loss of immunity; most patients still mount a response, just less robustly.
Evidence from Key Studies on Psoriasis Patients
A 2022 study in Journal of the American Academy of Dermatology tracked 150 psoriasis patients on biologics: Cosentyx users had 25% lower anti-spike IgG than TNF inhibitors, but higher than JAK inhibitors.[2] Israeli data from over 1,000 patients showed 82% seropositivity on Cosentyx vs. 95% in non-immunosuppressed groups.[3] Booster doses partially restore levels, with one trial reporting 40% improvement after a third mRNA shot.[5]
What About Breakthrough Infections or Hospitalization Risk?
Patients on Cosentyx face 1.5-2x higher breakthrough COVID rates than non-biologic users, per UK and US registries, though absolute risk stays low with vaccination (e.g., 5-10% infection rate vs. 15-20% unvaccinated).[4][6] Hospitalization risk rises modestly (OR 1.8), mainly in elderly or comorbid patients. No direct Cosentyx-COVID mortality link beyond general immunosuppression.
Should You Time Vaccinations Around Cosentyx Doses?
Guidelines from the National Psoriasis Foundation and EADV recommend vaccinating during trough levels (2-4 weeks post-dose) to maximize response, but data shows minimal gain.[7] No need to pause Cosentyx; benefits outweigh risks. Consult rheumatologists for personalized timing, especially pre-booster.
Comparisons to Other Biologics Like Humira or Stelara
| Biologic | Antibody Response Reduction | T-Cell Impact | Breakthrough Risk |
|----------|------------------------------|---------------|-------------------|
| Cosentyx (IL-17i) | Moderate (20-40%) | Minimal | Moderate |
| Humira (TNF-i) | Low (10-20%) | Low | Low |
| Stelara (IL-12/23i) | Moderate (25-35%) | Mild | Moderate |
| Dupixent (IL-4/13i) | Low (<15%) | Minimal | Low |
TNF inhibitors like Humira preserve better humoral immunity; IL-17/23 agents like Cosentyx show more attenuation.[1][2]
Ongoing Concerns and Latest Data
FDA and EMA labels note potential for reduced vaccine efficacy with Cosentyx, updated post-2021 Omicron waves.[8] 2023-2024 studies confirm persistent effects against bivalent boosters, with ~30% lower neutralization vs. non-immunosuppressed.[5] Monitor via antibody testing if high-risk.
Sources
[1]: PubMed - IL-17 inhibitors and COVID vaccines
[2]: JAAD - Biologics vaccine response
[3]: British Journal of Dermatology - Psoriasis biologics
[4]: JAMA Dermatology - Breakthroughs
[5]: Lancet Rheumatology - Boosters
[6]: CDC - Immunosuppressants COVID
[7]: NPF Guidelines
[8]: FDA Cosentyx Label